Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients
Geoffroy Venton(Inserm), Régis Costello(Inserm), Raphaëlle Fanciullino(Inserm), Jennifer Cautela(Hôpital Nord), K. Aïssi(Assistance Publique Hôpitaux de Marseille), Mihai Turcanu(Aix-Marseille Université), Robin Arcani(Inserm), Laure Farnault(Aix-Marseille Université), Julien Colle(Inserm), Franck Thuny(Assistance Publique Hôpitaux de Marseille), Pierre‐André Jarrot(Inserm), Vadim Ivanov(Hôpital de la Conception), Pauline Roché(Hôpital de la Conception), Pierre Suchon(Inserm), Cédric Mercier(Inserm), Safia Chebrek(Université d'Avignon et des Pays de Vaucluse)
Cited by 25
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal - Cardiovascular Imaging|2022|486
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
|Journal of the American Heart Association|2020|298
Meta-analysis of 65,734 Individuals Identifies TSPAN15 and SLC44A2 as Two Susceptibility Loci for Venous Thromboembolism
|The American Journal of Human Genetics|2015|274